Atypical Presentation and Aggressive Evolution of Primary CNS Lymphoma (PCNSL)

2018 ◽  
Vol 4 (1) ◽  
pp. 131-143
Author(s):  
Karan Topiwala ◽  
◽  
Karan Tarasaria ◽  
Jussie Lima ◽  
Xianyuan Song ◽  
...  
Keyword(s):  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
Atypical Presentation

First-line temozolomide therapy and MGMT status in elderly patients with primary CNS lymphoma

2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
M Glas ◽  
D Kurzwelly ◽  
P Roth ◽  
K Rasch ◽  
E Weimann ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
First Line

scholarly journals SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii2-ii2
Author(s):  
Eisei Kondo
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Primary Cns Lymphoma ◽  
High Dose Chemotherapy ◽  
Cns Lymphoma ◽  
High Dose ◽  
Hematopoietic Stem

Abstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDT-ASCT) is listed as a consolidation therapy option for primary central nervous system (CNS) lymphoma in the guidelines of western countries. The advantages of HDT-ASCT for primary CNS lymphoma as consolidation are believed to be high rates of long-term remission and lower neurotoxicity, even though its eligibility is limited to younger fit patients. In the Japanese guideline, HDT-ASCT for primary CNS lymphoma is however not recommended in daily practice, mainly because thiotepa was unavailable since 2011. The Japanese registry data for hematopoietic transplantation have shown that primary CNS lymphoma patients were treated with various HDT regimens and thiotepa-containing HDT was associated with better progression free survival (P=.019), lower relapse (P=.042) and a trend toward a survival benefit (Kondo E et al, Biol Blood Marrow Transplant 2019). A pharmacokinetic study of thiotepa(DSP-1958) in HDT-ASCT for lymphoma was conducted in 2017, and thiotepa was approved for HDT-ASCT in lymphoma this March, meaning that optimal HDT regimen for CNS lymphoma is now available in Japan. The treatment strategy of CNS lymphoma needs further development to improve survival and reduce toxicity.

scholarly journals Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Blood ◽  
2020 ◽  
Vol 136 (19) ◽  
pp. 2229-2232
Author(s):  
Kathryn Lurain ◽  
Thomas S. Uldrick ◽  
Ramya Ramaswami ◽  
Mark N. Polizzotto ◽  
Priscila H. Goncalves ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate
Sign in / Sign up

Export Citation Format

Share Document